SXR-1096

N/A

Report date: 2024/12/04 16:38:19
NME

Base Information

Drug NameSXR-1096
Drug Alias NameSXR-1096
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionKallikrein-5 inhibitorsKallikrein-7 inhibitorsKallikrein Related Peptidase 14 inhibitors
TargetsKallikrein-5Kallikrein-7Kallikrein Related Peptidase 14
Therapy Area/IndicationsNetherton Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwedenAustriaGermany +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSixera Pharma
China Registration ClassN/A

Develop Information

Active CompaniesSixera Pharma
Inactive CompaniesN/A
Active IndicationsNetherton Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A